Baddeck Home Support Workers vote 100% in favour of a strike
"We believe in the value of home support to the health care system; we know how important it is to help people stay in their homes longer. We deserve fair pay; we deserve a safe working environment; and we deserve stable working hours'
Share
'After four years out of contract and seven months of bargaining, we're tired of waiting for the Nova Scotia government and our employer to recognize our issues,' said Trish Lewis-Pierrard, president of CUPE 4354, the local union that represents the workers of VCHSS.
Like many other home support Continuing Care Assistants (CCAs), home support workers at VCHSS do not have guaranteed hours of work. This means that their hours fluctuate week to week and are subject to change based on the client's needs. Yet, despite this instability, all home support workers are expected to own their own reliable vehicle with insurance and a Nova Scotian registration.
'We had one new hire in 2024. The only new hire that stayed before that was in 2018,' said Lewis-Pierrard. 'When I started in 2007, we had 26 CCAs on staff. Now we have 16. That isn't sustainable. New graduates need to want to come to VCHSS for their career and stay, and that's not going to happen with unstable hours and low wages.'
'It's impossible for CCAs in this sector to make any long term plans,' said CUPE Home Support Sector Coordinator Kathy MacLeod. 'Every week, their hours and pay can change based on the clients. This doesn't happen in any other sector. No CCA in long term care or at the hospitals has their pay change depending on how many residents or patients they see in a day.'
Another issue remaining on the table is improved workplace safety language. Home support workers are expected to enter client homes unaccompanied to provide care, often in remote areas without cell service or reception. The local is fighting for a more clear and effective process for when incidents arise and better protections for the CCAs working in the field.
'None of us want to strike, but we are all prepared to if that's what it takes for our issues to be addressed. We believe in the value of home support to the health care system; we know how important it is to help people stay in their homes longer. We deserve fair pay; we deserve a safe working environment; and we deserve stable working hours,' finished Lewis-Pierrard.
CUPE 4354 is the third CUPE Home Support local to take a positive strike vote.
:so/cope491
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
SÖDERTÄLJE, Sweden--(BUSINESS WIRE)--Anocca AB ('Anocca' or the 'Company'), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ~440 million (USD ~46 million) in financing. The additional capital will be used to drive the continued progress of VIDAR-1, Anocca's gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca's preclinical pipeline. The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors. Recruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and The Netherlands. Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: 'We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.' Johan Andersson, Chairman of Mellby Gård, commented: 'We have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies.' SEB Corporate Finance acted as financial advisor to Anocca on the finalisation of the transaction, and Mannheimer Swartling and HWF Advokater have acted as legal advisors. ENDS About Anocca Anocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity. These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca's TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca's facilities in Södertälje, Sweden. 130+ staff from 40+ nations work at Anocca. About the VIDAR-1 clinical programme VIDAR-1 is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase I/II studies. Phase I is currently conducted at eight sites in four countries with additional countries and sites in phase II. Patients will be eligible to enrol if they have an HLA, and KRAS mutation, matching an available product. More information about the clinical trial can be found at the EU's clinical trials website. About KRAS and PDAC Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect around 90% of pancreatic cancer patients. The five-year survival rate of patients with PDAC is less than 10% (1). Despite recent advances there are no definitive treatments for advanced patients at present (2). References 1. Rawla et al (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 10(1):10–27. doi: 10.14740/wjon1166 2. Hu & O'Reilly (2023). Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol 21, 7–24. doi: 10.1038/s41575-023-00840-w
Associated Press
4 hours ago
- Associated Press
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--Aug 18, 2025-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company') plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to the timing of the Company's financial reporting and the Company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View source version on CONTACT: PureTech Public Relations [email protected] Investor Relations [email protected] KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS SOURCE: PureTech Health plc Copyright Business Wire 2025. PUB: 08/18/2025 02:00 AM/DISC: 08/18/2025 01:59 AM
Business Wire
3 days ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
